Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Copyright © 2019. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 201(2019) vom: 20. Apr., Seite 48-54
1. Verfasser: Clifton, G Travis (VerfasserIn)
Weitere Verfasser: Peace, Kaitlin M, Holmes, Jarrod P, Vreeland, Timothy J, Hale, Diane F, Herbert, Garth S, Litton, Jennifer K, Murthy, Rashmi K, Lukas, Jason, Peoples, George E, Mittendorf Elizabeth, A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Breast cancer HER2 Monoclonal antibody Peptide vaccine mehr... Trastuzumab Antineoplastic Agents, Immunological HER2 peptide (369-377) Immunologic Factors Peptide Fragments Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1 Receptor, ErbB-2 EC 2.7.10.1 P188ANX8CK
Online verfügbar Volltext